Skip to main content
. 2019 Jul 27;11(8):688. doi: 10.3390/v11080688

Figure 5.

Figure 5

Species–specific plaque reduction microneutralization (PRMN) profiling. (A) PRMN activity of measles virus-immune (guinea pig) antisera. (B) PRMN activity of canine distemper virus-immune (ferret) antisera. (C) PRMN activity of measles virus-immune (human) antisera. PRMN was performed on the indicated cell lines. Briefly, a fixed amount of virus was preincubated with a decreasing concentration of antisera before infection of cells. The amount of virus in the control wells was set to 100%. The 50% end-point titer (neutralizing dose [ND50]) virus-antiserum pair was determined and converted into mIU/mL. Values and error bars represent SD from two independent experiments (Used with permission of Mayo Foundation for Medical Education and Research).